Skip to main content
SpringerLink
Log in

Chemotherapie, PARP-Inhibition, Immuntherapie

Systemische Therapie des duktalen Pankreaskarzinoms

  • Zertifizierte Fortbildung
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3

Literatur

  1. https://tinyurl.com/Krebs-in-Deutschland-2015-2016, abgerufen am 16. April 2021

  2. Rahib L et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-21

  3. Quante AS et al. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030.Cancer Med. 2016;5(9):2649-56

  4. Oettle H et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267-77

  5. Neoptolemos JP et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073-81

  6. Uesaka K et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248-57

  7. Oettle H et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473-81

  8. Neoptolemos JP et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open- label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011-24

  9. Conroy T et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395-406

  10. Tempero MA et al. APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine for surgically resected pancreatic adenocarcinoma. J Clin Oncol. 2019;37(15_suppl):4000

  11. Philip PA et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020;5(3):285-94

  12. Perri G et al. Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-Paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma. JAMA Surg. 2020;155(9):832-9

  13. Suker M et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta- analysis. Lancet Oncol. 2016;17(6):801-10

  14. Sohal DP et al. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(23):2784-96

  15. Burris HA et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-13

  16. Conroy TF et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-25

  17. Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703

  18. Moore MJ et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-6

  19. Von Hoff DD et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A Phase I/II Trial. J Clin Oncol. 2011;29(34):4548-54

  20. Goldstein D et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2):dju413

  21. Cunningham D et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513-8

  22. Herrmann R et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25(16):2212-7

  23. O'Reilly EM et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 2020;38(13):1378-88

  24. Lowery MA et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist. 2011;16(10):1397-402

  25. Golan et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317-27

  26. Golan T et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer J Clin Oncol. 2021;39(3_suppl):Abstr 378

  27. https://www.leitlinienprogramm-onkologie.de/leitlinien/pankreaskarzinom, abgerufen am 16 April. 2021

  28. Marabelle A et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1-10

  29. Wang-Gillam A et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545-57

  30. Pelzer UI et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676-81

  31. Oettle H et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014;32(23):2423-9

  32. Gill S et al. PANCREOX: A randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34(32):3914-20

  33. Sohal DPS et al. Metastatic pancreatic cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(24):2545-56

  34. https://www.onkopedia.com/de/onkopedia/guidelines/pankreaskarzinom/@@guideline/html/index.html, abgerufen am 20. April 2021

Download references

Author information

Authors and Affiliations

  1. Med. Klinik III der LMU München Großhadern, Marchioninistr. 15, 81377, München, Deutschland

    Volker Heinemann

  2. - Medizinische Klinik u. Poliklinik III -, Campus Großhadern d. LMU München, Marchioninistraße 15, 81377, München, Deutschland

    C. Benedikt Westphalen

  3. Med. Klinik III der LMU München, Marchioninistr. 15, 81377, München, Deutschland

    Stefan Böck

Authors
  1. Volker Heinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Benedikt Westphalen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Böck
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen. Die Autoren legen folgende potenzielle Interessenkonflikte offen: V. Heinemann: Honoraria (ich selbst: Merck, Amgen, Roche, Sanofi, Sirtex, Servier, Pfizer, Pierre-Fabre, Astra-Zeneca); Consulting oder Advisory Board (ich selbst: Merck, Amgen, Roche, Sanofi, Sirtex, BMS, MSD, Novartis, Boehringer Ingelheim, Servier, Pierre-Fabre, Celgene, Terumo); Forschungsförderung (mein Institut: Merck, Amgen, Roche, Sanofi, Boehringer Ingelheim, Sirtex, Servier); Reisemittel (Merck, Roche, Amgen, Sirtex, Bayer, Servier); C. B. Westphalen: Beratungstätigkeit/Honorare: Chugai, Bayer, Celgene, GSK, MSD, Merck, Ipsen, Roche, Servier, SIRTeX, Taiho BMS, Celgene, Shire/Baxalta, Rafael Pharmaceuticals, RedHill, Roche; Stefan Böck: Beratungs- bzw. Gutachtertätigkeit: Servier, Incyte, Fresenius, AstraZeneca. Honorare für wissenschaftliche Vorträge: Celgene, Servier

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heinemann, V., Westphalen, C. & Böck, S. Systemische Therapie des duktalen Pankreaskarzinoms. InFo Hämatol Onkol 24, 37–47 (2021). https://doi.org/10.1007/s15004-021-8653-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8653-3

Search

Navigation